A comprehensive analysis of CBER experience with AAV gene therapy IND submissions

a-comprehensive-analysis-of-cber-experience-with-aav-gene-therapy-ind-submissions
  • Comment
  • Published:

Nature Biotechnology (2026) Cite this article

An analysis of Investigational New Drug (IND) submissions to the US Food and Drug Administration (FDA) from 1995 to 2025 reveals a rapid growth in adeno-associated virus (AAV) development over three decades and highlights common reasons for regulatory holds that should be considered for successful product development.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$39.99 / 30 days cancel any time

Learn more

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year only $21.58 per issue

Learn more

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L. & Gao, G. Signal Transduct. Target. Ther. 6, 53 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L. & Gao, G. Signal Transduct. Target. Ther. 9, 78 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Li, C. & Samulski, R. J. Nat. Rev. Genet. 21, 255–272 (2020).

    Article  CAS  PubMed  Google Scholar 

  4. Duan, D. et al. J. Virol. 72, 8568–8577 (1998).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Dong, B., Nakai, H. & Xiao, W. Mol. Ther. 18, 87–92 (2010).

    Article  CAS  PubMed  Google Scholar 

  6. Gao, G. et al. J. Virol. 78, 6381–6388 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Maguire, A. M. et al. N. Engl. J. Med. 358, 2240–2248 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lapteva, L., Purohit-Sheth, T., Serabian, M. & Puri, R. K. Mol. Ther. Methods Clin. Dev. 19, 387–397 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Nathwani, A. C. et al. N. Engl. J. Med. 371, 1994–2004 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Mingozzi, F. & High, K. A. Blood 122, 23–36 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Russell, S. et al. Lancet 390, 849–860 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Foust, K. D. et al. Nat. Biotechnol. 27, 59–65 (2009).

    Article  CAS  PubMed  Google Scholar 

  13. Pacak, C. A. et al. Circ. Res. 99, e3–9 (2006).

    Article  CAS  PubMed  Google Scholar 

  14. Srivastava, A. Curr. Opin. Virol. 21, 75–80 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wang, L. et al. Mol. Ther. 18, 118–125 (2010).

    Article  CAS  PubMed  Google Scholar 

  16. Grimm, D. et al. J. Virol. 82, 5887–5911 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hinderer, C. et al. Hum. Gene Ther. 29, 285–298 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Laforet, G. A. Hum. Gene Ther. 36, 64–76 (2025).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Z. Ye, K. Schultz, S. Butler, A. Harmon, R. Vatsan, D. Gavin, A. Harvan and P. Kurs for valuable review, feedback and advice. The opinions presented in this article are those of the authors and do not necessarily represent the views or policies of FDA. This article does not include all programs, policies and incentives available for development of novel therapies for rare diseases.

Author information

Authors and Affiliations

  1. Office of Therapeutic Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA

    Sojin Bing, Takele Argaw, Megha Kaushal & Ronit Mazor

Authors

  1. Sojin Bing
  2. Takele Argaw
  3. Megha Kaushal
  4. Ronit Mazor

Corresponding author

Correspondence to Ronit Mazor.

Ethics declarations

Competing interests

All authors are employed by the US Food and Drug Administration.

Supplementary information

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bing, S., Argaw, T., Kaushal, M. et al. A comprehensive analysis of CBER experience with AAV gene therapy IND submissions. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03378-9

Download citation

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41587-026-03378-9